Page 5,560«..1020..5,5595,5605,5615,562..5,5705,580..»

Scientists develop a biodegradable nanoparticle that effectively resolves inflammation

Posted: Published on March 19th, 2013

Collagen IV-targeted polymeric nanoparticles (shown in pink) are home to injured tissue, post-injection, in the blood. Credit: Farokhzad Lab (Phys.org) Inflammation is the body's natural defense mechanism against invading organisms and tissue injury. In acute inflammation, the pathogen or inflammatory mediators are cleared away and homeostasis is reached, however in chronic inflammatory states, this resolving response is impaired, leading to chronic inflammation and tissue damage. It is now widely believed that an impaired resolution of inflammation is a major contributing factor to the progression of a number of devastating diseases such as atherosclerosis, arthritis, and neurodegenerative diseases, in addition to cancer. Since the level of inflammation in these diseases is very hightargeted therapeutic solutions are required to help keep inflammation contained. A new study from researchers at Brigham and Women's Hospital (BWH), Columbia University Medical Center, Icahn School of Medicine at Mount Sinai, and Massachusetts Institute of Technology presents the development of tiny nanomedicines in the sub 100 nm range (100,000 times smaller than the diameter of a human hair strand) that are capable of encapsulating and releasing an inflammation-resolving peptide drug. The authors showed that these nanoparticles are potent pro-resolving nanomedicines, capable of selectively homing to sites of tissue … Continue reading

Comments Off on Scientists develop a biodegradable nanoparticle that effectively resolves inflammation

Kryptonite for cancer cells

Posted: Published on March 19th, 2013

Mansoor Amiji, Distinguished Professor and Chair of the Department of Pharmaceutical Sciences at Northeastern University. Amiji's field of expertise includes Drug Delivery and Nanomedicine, the application of nanotechnology for medical diagnosis, imagining, and therapy. (Phys.org) Every available cancer drug is susceptible to resistance, according to Mansoor Amiji, Distinguished Professor and chair of the Department of Pharmaceutical Sciences. Tumors grow more quickly than blood vessels, so these unruly masses of cells receive very little oxygen and nutrients, which means they know just how to survive under harsh conditions. They make miniature pumps to actively dispel anything that doesn't serve them well (like drugs), and they evade all the checks and balances that normally maintain healthy cell populations. Each of these supercell powers is coded in the cancer's DNA. In theory, turning off the right genes would turn off the superpowers, according to Amiji. A method called RNA interference does exactly that. By inhibiting protein production of specific sections of DNA, so-called small interfering RNA, or siRNA, can shut down the activity of individual genes. But this is easier said than done. The siRNA molecules are incredibly finicky molecules, which Amiji likened to a picky houseguest who needs everything just so. "They're … Continue reading

Comments Off on Kryptonite for cancer cells

New nanomedicine resolves inflammation, promotes tissue healing

Posted: Published on March 19th, 2013

Public release date: 18-Mar-2013 [ | E-mail | Share ] Contact: Karin Eskenazi ket2116@columbia.edu 212-342-0508 Columbia University Medical Center NEW YORK, NY (March 18, 2013) A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury. The nanoparticles, which were successfully tested in mice, have potential for the treatment of a wide array of diseases characterized by excessive inflammation, such as atherosclerosis. The study was published today in the online edition of the Proceedings of the National Academy of Sciences. A key way in which the body protects itself against infection or injury is through acute inflammation. Ideally, this response first promotes the clearance of pathogens or damaged tissue; then, through a process called inflammation resolution, it clears cellular debris and inflammatory mediators and restores the tissue to its normal state. However, in many conditions, including heart disease, arthritis, and neurodegenerative diseases, the inflammatory process never resolves, leading to tissue damage. "A variety of medications can be used to control inflammation. Such treatments, however, usually have significant … Continue reading

Comments Off on New nanomedicine resolves inflammation, promotes tissue healing

Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS® …

Posted: Published on March 18th, 2013

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL. The sBLA submission includes data demonstrating ADCETRIS activity in managing HL and sALCL when used in the retreatment setting, as well as beyond the 16 cycles described in our current label, while retaining a manageable safety profile, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Our goal is to broaden the ADCETRIS U.S. labeling claims to provide both patients and physicians the opportunity to incorporate ADCETRIS into additional HL and sALCL treatment settings. The sBLA submission includes data that support these uses and we look forward to the regulatory outcome. The sBLA is based on results from a phase II clinical trial with two treatment arms. … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS® …

Regen BioPharma Receives IND # From FDA for HemaXellerate

Posted: Published on March 18th, 2013

SAN DIEGO, CA--(Marketwire - Mar 18, 2013) - Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. ( PINKSHEETS : BMSN ), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia. As part of the clinical trial approval process, the FDA will issue comments on the proposed trial which must be addressed to the FDA's satisfaction before patient dosing is initiated.The clinical trial will treat ten patients with aplastic anemia that have not responded to conventional therapy and lack a bone marrow donor. "We are pleased that the company has been issued an IND number and has taken the first step towards regulatory approval in the USA," said David Koos, Chairman & CEO of Bio-Matrix. "We have compiled an internationally-renowned team, consisting of corporate and academic partners, which cover the manufacturing, regulatory, and medical aspects of the project.Members of the team have previously published with Regen the scientific rational for the trial in a peer-reviewed publication in January of last year which may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf." HemaXellerate is a patient-specific composition of cells that have previously been demonstrated to … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Regen BioPharma Receives IND # From FDA for HemaXellerate

Cytomedix Announces Centers for Medicare & Medicaid Services (CMS) Issuance Of Reimbursement Coding for Autologous PRP …

Posted: Published on March 18th, 2013

GAITHERSBURG, MD--(Marketwire - Mar 18, 2013) - Cytomedix, Inc. ( OTCQX : CMXI ) (the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that the Center for Medicare & Medicaid Services (CMS) has issued reimbursement coding and claims payment instructions to its regional contractors for the use of autologous PRP in chronic non-healing wounds.The assignment of a Healthcare Common Procedure Coding System (HCPCS) code establishes the reimbursement mechanism for physicians and other providers submitting claims for services provided to Medicare beneficiaries. A new HCPCS code, G-0460, has been assigned for: "Autologous platelet rich plasma for chronic wounds/ulcers, including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment." Martin Rosendale, Chief Executive Officer of Cytomedix, commented, "The assignment of a HCPCS code for the use of AutoloGel is another critical element to the near term clinical treatment of chronic non-healing wounds with commercial reimbursement.We recently received protocol approval under the Coverage with Evidence Development (CED) program, and detailed coding and payment instructions have now been issued to CMS' regional contractors and fiscal intermediaries.Our interaction with CMS continues to be productive and appropriately collaborative.We are enthusiastic that Medicare beneficiaries will … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Cytomedix Announces Centers for Medicare & Medicaid Services (CMS) Issuance Of Reimbursement Coding for Autologous PRP …

BioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments

Posted: Published on March 18th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2012 and highlighted its fourth quarter and recent corporate accomplishments. Fourth Quarter and Recent Highlighted Corporate Accomplishments We have positioned 2013 to be a very pivotal year in the development of our product opportunities as BioTime begins human clinical trials for Renevia, OncoCyte initiates its PanC-Dx clinical study, LifeMap Sciences expands its revenue generating product offerings, and we move to close our transaction with BAC and Geron, said Michael D. West, Ph.D., BioTime's President and Chief Executive Officer. The proceeds from our recent equity financings will support the funding of our operations and cash commitment to BAC through this year. Financial Results Revenue For the quarter ended December 31, 2012, on a consolidated basis, total revenue was $1.2 million, down $0.5 million from $1.7 million for the same period one year ago. The decrease in fourth quarter revenue is primarily attributable to lower grant revenue related to the completion of BioTimes research grant from the California Institute for Regenerative Medicine (CIRM), and a decrease in the sale of research products, partially offset by subscription and advertising revenues from LifeMap … Continue reading

Posted in Stem Cell Human Trials | Comments Off on BioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments

IMAGE Skincare Announces Revolutionary New Oxygenating Treatment

Posted: Published on March 18th, 2013

WEST PALM BEACH, Fla., March 18, 2013 /PRNewswire/ --IMAGE Skincare unveiled its revolutionary oxygenating treatment last week at a series of parties hosted all over the world. Combining the latest technology in oxygen and stem cell therapies, the company at the forefront of innovation in skincare has created the ultimate anti-aging spa treatment: The O2 Lift. "The best part about this treatment is that recipients can expect to leave with an immediate result. Skin feels softer, smoother, and more radiant with just one treatment," said IMAGE Skincare Founder and CEO Janna Ronert. The O2 Lift is a five-step luxury spa treatment that exfoliates and oxygenates the skin while infusing plant-derived stem cells, peptides, and a high concentration of enzymatic botanicals to leave skin glowing and illuminated. "As a plastic surgeon, I have seen the benefits of oxygen therapy in cell regeneration. We wanted to bring that same technology to the cosmetic market, and we're one of the few companies in the world who has been able to harness the power of oxygen in a cosmetic application," said President and Medical Director of IMAGE Skincare, Dr. Marc Ronert. "There is no other product on the market like this one." The goal … Continue reading

Comments Off on IMAGE Skincare Announces Revolutionary New Oxygenating Treatment

Stimulating stem – cell growth naturally

Posted: Published on March 18th, 2013

Inside Out By Cory Quirino Philippine Daily Inquirer The excitement over the tremendous healing and anti-aging power of stem cells continues to build up toward a frenzied acceptance of this new wonder treatment. But stem cells are not new; they are as old as time itself. They have been and always will be inside us. The approach, however, in harvesting, cultivating and reinfusing stem cells into ones own system is expensive and not within the reach of the average person. The public is also confused with an avalanche of information on which stem-cell clinic to consult, what stem-cell approach is best, what kind of stem cells to usewhether from a sheep or ones own adult stem cell. Despite the Department of Healths guidelines regarding the superior safety of using adult stem cells over animal sources, the debates continue. If one were to choose adult stem cells, should it be autologous (coming from your own), or are Russian bone marrow stem cells better than the Japanese womens placenta stem cells? Better yet, why not have your very own bone marrow stem cells taken from the back of your hip? Experts claim that the procedure is relatively painless and 100-percent effective. Nobody … Continue reading

Comments Off on Stimulating stem – cell growth naturally

Local Vet Seeing Benefits Of Stem Cell Treatment

Posted: Published on March 18th, 2013

PITTSBURGH (KDKA) The debate has raged for years about stem cells, but Butler County Veterinarian Mike Hutchinson is completely sold on their effectiveness. So is a family from Baden after their dog was treated with stem cells. Just before thanksgiving, Sadies severe skin allergies led to blisters and a nasty rash on her belly. Traditionally, we use it for arthritis, we use it for ligament issues, bone fractures, things like that. But this dog had an immune system. Its allergic to everything under the sun, Dr. Mike Hutchinson said. After trying the standard of care, Dr. Mike suggested stem cells. We were at a loss, so we just chose to do this and within the day we brought her home we said, What do we do? because she was pretty raw and sore. Within five days, she was almost completely healed, Debbie Valosio said. Stem cells are a repair cell that we take from fat and its just that a repair cell. One of its functions its a potent immuno-modulator which means it helps to calm the immune system down if it is over-reacting, not to the point where it makes it too low, but it calms it down, Dr. … Continue reading

Comments Off on Local Vet Seeing Benefits Of Stem Cell Treatment

Page 5,560«..1020..5,5595,5605,5615,562..5,5705,580..»